Vicor's AI Power Story Gains Momentum, but Valuation Still Requires Discipline

What happened

Since the July 21 report, Vicor has raised Q3 revenue guidance twice on stronger AI-related demand and secured additional licensing agreements, reinforcing its position in high-power delivery for AI processors. Management also announced plans for new ChiP Fab sites to expand capacity, addressing a bottleneck that previously capped shipment growth. The company now publicly targets $2.5 billion in sales with 70% gross margins and 40% net income, implying a significant long-term ramp from current levels. With a $380 million backlog and high-margin royalty income, operating momentum appears intact, but these targets are aspirational and hinge on flawless execution and sustained hyperscaler spending. The stock likely responded strongly to these announcements, further compressing valuation and reducing margin for error absent proof of royalty durability and capacity expansion timelines.

Implication

The raised guidance and licensing deals are positive signals that demand remains robust, but they do not eliminate the risk that royalties are usage-based and could be lumpy quarter-to-quarter. The new ChiP Fab sites, if committed with firm timelines, would address a major constraint, but until we see concrete capex and schedule, the capacity bottleneck may persist. The $2.5B sales and 70% gross margin targets are ambitious; achieving them would require capturing substantial share in a competitive power delivery market and successfully ramping multiple fabs. Given the stock's likely appreciation since July, the valuation may be even more stretched than the 70x earnings and 80x EV/EBITDA observed then, reducing downside protection. Therefore, while the long-term story is compelling, the current setup still favors watching rather than chasing, and a pullback toward the previously identified attractive entry near $175 would offer a more favorable risk-reward.

Thesis delta

The prior WAIT rating was based on valuation and the need for proof on royalties and capacity. The new information partly addresses the capacity concern by announcing new Fab sites, and the raised guidance supports demand strength, but it does not yet confirm royalty durability or provide a dated Fab 2 timeline. Consequently, while the thesis has improved on the supply side, the valuation risk has likely increased, so we maintain a WAIT stance but with a slightly more positive tilt if the stock pulls back to a more reasonable level.